| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
| |
|
For the Three Months Ended
April 30, |
|
|
For the Six Months Ended
April 30, |
|
| |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
| Net income/(loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(997 |
) |
|
$ |
(1,399 |
) |
|
$ |
(1,908 |
) |
|
$ |
(3,010 |
) |
| Cancer Vaccines |
|
|
(913 |
) |
|
|
(1,423 |
) |
|
|
(1,871 |
) |
|
|
(2,780 |
) |
| Anti-Viral Therapeutics |
|
|
(416 |
) |
|
|
(757 |
) |
|
|
(898 |
) |
|
|
(1,661 |
) |
| Other |
|
|
19 |
|
|
|
(9 |
) |
|
|
16 |
|
|
|
(16 |
) |
| Total |
|
$ |
(2,307 |
) |
|
$ |
(3,588 |
) |
|
$ |
(4,661 |
) |
|
$ |
(7,467 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
2,770 |
|
|
$ |
3,589 |
|
|
$ |
5,326 |
|
|
$ |
7,469 |
|
| Less non-cash stock-based compensation |
|
|
(1,227 |
) |
|
|
(1,745 |
) |
|
|
(2,290 |
) |
|
|
(4,099 |
) |
| Operating costs and expenses excluding non-cash stock-based compensation |
|
$ |
1,543 |
|
|
$ |
1,844 |
|
|
$ |
3,036 |
|
|
$ |
3,370 |
|
| Operating costs and expenses excluding non-cash stock-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
620 |
|
|
$ |
733 |
|
|
$ |
1,218 |
|
|
$ |
1,402 |
|
| Cancer Vaccines |
|
|
523 |
|
|
|
716 |
|
|
|
1,111 |
|
|
|
1,196 |
|
| Anti-Viral Therapeutics |
|
|
212 |
|
|
|
388 |
|
|
|
517 |
|
|
|
760 |
|
| Other |
|
|
188 |
|
|
|
7 |
|
|
|
190 |
|
|
|
12 |
|
| Total |
|
$ |
1,543 |
|
|
$ |
1,844 |
|
|
$ |
3,036 |
|
|
$ |
3,370 |
|
| |
|
April 30,
2023 |
|
|
October 31,
2022 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
11,682 |
|
|
$ |
16,921 |
|
| Cancer Vaccines |
|
|
10,638 |
|
|
|
9,442 |
|
| Anti-Viral Therapeutics |
|
|
4,953 |
|
|
|
3,811 |
|
| Other |
|
|
326 |
|
|
|
238 |
|
| Total |
|
$ |
27,599 |
|
|
$ |
30,412 |
|
|